GL1X · GenesisL1 explorer

MolNFT v1 · #118047 · protein

Crystal structure of lanosterol 14-alpha demethylase with intact transmembrane domain bound to itraconazole

5EQB: “Crystal structure of lanosterol 14-alpha demethylase with intact transmembrane domain bound to itraconazole”. X-ray diffraction, 2 ligands (HEM, 1YN), 5 pockets (best druggability 0.87). MolNFT v1 #118047 on GenesisL1: 3D structure…

PDB
5EQB
Type
protein
Length
531 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Lanosterol 14-alpha demethylase
EC
1.14.13.70
UniProt
P10614
Ligands
HEM, 1YN
Pockets
5 · best druggability 0.87

Structure

x-ray diffraction · 1 distinct chain · 52% helix, 10% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ALanosterol 14-alpha demethylase (EC 1.14.13.70)protein53152% helix, 10% strandP10614

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · chains A
  • 1YN · 2-[(2R)-butan-2-yl]-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18820.870.8975HEM, 1YN
22680.600.7833empty
31810.580.8137empty
41320.450.7724empty
5520.280.7611empty

Compared structures

  • 5EQB · Crystal structure of lanosterol 14-alpha demethylase with intact transmembrane domain… · the same entry in another collection · chain A against A, TM-score 1.00
  • P10614 · AlphaFold monomer V2.0 prediction for lanosterol 14-alpha demethylase (P10614) · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.